|
||
| Gilenya News Channel |  |
|
|
|||||
|
|||||
|
|||||
| MS NEWS ARCHIVES: by week | |||||
| July 2013 | |||||
| September 2013 | |||||
| October 2013 | |||||
| June 2014 | |||||
| July 2014 | |||||
| January 2015 | |||||
| February 2015 | |||||
| March 2015 | |||||
| April 2015 | |||||
| May 2015 | |||||
| July 2015 | |||||
| March 2016 | |||||
| April 2016 | |||||
| May 2016 | |||||
| June 2016 | |||||
 |
|||||
 |
|||||
 |
|||||
 |
|||||
 |
|||||
 |
|||||
| HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS | |||||
 |
|||||
| |||||
| |||||
 Click to view 1280 MS Walk photos! | |||||
|
|||||
|
|||||
|
|||||
Wednesday
Disease-modifying treatments for MS – a review of approved medications: STUDY
Pegylated Interferon Beta-1a for Multiple Sclerosis: VIDEO
The MD Magazine Peer Exchange "Modifying the Course of Multiple Sclerosis in New Ways: The Latest Advances in Treatment" features a distinguished panel of physician experts discussing key topics in multiple sclerosis (MS) research and management, including the latest insights into MS pathophysiology, new medication options and their application in clinical practice, and more.
Read more »
Labels: Aubagio, Lemtrada, Plegridy, Tecfidera, Video
Tuesday
Cost-utility of Gilenya (fingolimod) compared with Tecfidera (dimethyl fumarate) in highly active relapsing-remitting multiple sclerosis (RRMS) in England: STUDY
Wednesday
FREE MS RESEARCH UPDATE: a comprehensive overview of research findings on all of the FDA-approved disease-modifying therapies, as well as many experimental treatments
This year's expanded MS Research Update incorporates new information about the approved disease-modifying therapies (DMTs), as well as numerous experimental drugs currently under investigation for the long-term treatment of multiple sclerosis (MS). Highlights and recent research results are provided for each drug. Please note that symptom-management drugs are not included in this report.
DOWNLOAD YOUR FREE PDF OR ORDER A FREE COPY
Labels: Aubagio, Avonex, Betaseron, Copaxone, Lemtrada, Rebif, Rituxan-Rituximab, Tecfidera, Tysabri
Saturday
This Could Be Game-Changing News in the Battle Against Multiple Sclerosis
For a disease that affects more than 400,000 people in the United States and approximately 2.5 million around the globe, multiple sclerosis is arguably not getting its fair share of attention from drug developers and researchers. According to the National Institutes of Health, which has an annual budget near $40 billion, only $115 million is expected to be spent on MS research in 2015.
Read more »
Labels: Aubagio, Avonex, Daclizumab, Stem Cell, Tecfidera
Sunday
Wow! It's no wonder MS is seen as a Cash Cow: THESE MS DRUGS BROUGHT IN THE MOST MONEY LAST YEAR
Teva
soaring out in front on a single product and it is no surprise that the
Generics pack are waiting in the rear ready for the copaxone patents to
expire starting May 2014. However Biogen are backing the most winners
with a staggering $5.8 billion worth of business. #2 Avonex Biogen Idec $3.0 billion
#3 Gilenya Novartis $1.9 billion
#4 Tysabri Biogen Idec $1.7 billion
#5 Betaseron Bayer $1.1 billion
#6 Tecfidera Biogen Idec $0.9 billion
#7 Rebif EMD serono $0.6 billion
#8 Ampyra Biogen Idec $0.3 billion
#9 Aubagio Sanofi $0.2 billion
#10 Extavia Novartis $0.2 billion
Read more »
Labels: 20 Best Stories & Studies, Ampyra, Aubagio, Avonex, Betaseron, Copaxone, Extavia, Rebif, Tecfidera, Tysabri
Solid growth from Tecfidera (Dimethyl fumarate) in the US and OUS
Click here to read more
Labels: Tecfidera
VIDEO: Dr. Timothy Vollmer
 |
| Dr. Timothy Vollmer |
There appears to be several different factors. One is genetics; the disease is more prevalent in people from Northern Europe. The second one is low Vitamin D levels early in life, and possibly in in-utero, increase the risk of MS subsequently," University of Colorado Doctor Tim Vollmer said.
He says people in Colorado are normally diagnosed with low-levels of Vitamin D. Some experts believe Vitamin D levels may be low in the state because of Coloradan's use of sunscreen.
Vollmer says new MS research and treatments are progressing at a remarkable rate.
"The field Multiple Sclerosis is one of the most rapidly evolving fields of medicine right now. We have eight FDA therapies and three that are likely to be approved within the next year to 18 months. In the last year or so, we've developed a new blood test that would identify patients who are at risk of some of the serious side effects of the drugs. As a consequence, we can now identify people who are likely to do very well on a certain drug with a very low risk," Vollmer said.
Read more »
Labels: 100 MOST POPULAR, Dr. Timothy Vollmer, Tecfidera, Tysabri, Video
Data Show Declining Use of Injectables as Oral Multiple Sclerosis Therapies Gain Traction
Saturday
HOW MS MEDICATIONS DIFFER FROM EACH OTHER
Read more »
Labels: Aubagio, Avonex, Betaseron, Copaxone, Extavia, Novantrone, Rebif, Tecfidera, Tysabri
Tecfidera Captures the Largest U.S. Neurologist-Reported Patient Share Among Oral Disease-Modifying Multiple Sclerosis Therapies Ten Months Post-Launch
Tecfidera Is Off to a Quick Start
Merck KGaA shores up Rebif defenses to fend off new MS rivals
FREE MS RESEARCH UPDATE: a comprehensive overview of research findings on all of the FDA-approved disease-modifying therapies, as well as many experimental treatments
This year's expanded MS Research Update incorporates new information about the approved disease-modifying therapies (DMTs), as well as numerous experimental drugs currently under investigation for the long-term treatment of multiple sclerosis (MS). Highlights and recent research results are provided for each drug. Please note that symptom-management drugs are not included in this report.
DOWNLOAD YOUR FREE PDF OR ORDER A FREE COPY
Labels: Aubagio, Avonex, Betaseron, Copaxone, Extavia, Lemtrada, Rebif, Rituxan, Tecfidera, Tysabri
"COPAXONE IS HEADED OFF A CLIFF: It's painfully clear that generic competitors such as Mylan, Momenta, and Novartis' Sandoz unit will roll out generic Copaxone on time"
Oral MS drugs could exacerbate Copaxone's decline. Meanwhile,
the three main oral MS drugs -- Novartis' Gilenya, Biogen's Tecfidera,
and Sanofi's Aubagio -- could all bury Copaxone in its key U.S. market. Click to read how fast these treatments have been selling, despite their limited time on the market.
Labels: Aubagio, Copaxone, Tecfidera
Friday
Biogen Idec Inc: Tecfidera Continues Its Blistering Pace
The
company's new oral alternative to its top-selling Avonex racked up $286
million in third quarter sales, far above the $200 million forecast by
some industry analysts. Its rapid roll-out helped it capture $876
million in revenue in 2013, including $398 million in the fourth
quarter. For comparison, in the most recent quarter reported, competitor
drugs Gilenya earned $521 million and Aubagio by brought in about $60
million. read more
Labels: Aubagio, Avonex, Tecfidera
Biogen Idec Inc's high profile new multiple sclerosis drug Tecfidera won European approval
Sanofi MS Drug Added With Genzyme Fails to Win FDA Approval
Sanofi (SAN) failed to win U.S. regulatory
approval for its multiple sclerosis drug Lemtrada, denting the
company’s ambitions of capturing a larger share of the $20
billion market for the disease.
The U.S. Food and Drug Administration said Sanofi’s Genzyme
unit didn’t submit evidence from “adequate and well-controlled
studies” showing that the benefits of Lemtrada outweigh its
side effects, the Paris-based company said in a statement today.
Sanofi disagrees with the conclusion and said it will appeal.Lemtrada, which was approved in the European Union in September, was a key part of Sanofi’s $20.1 billion acquisition of Genzyme in 2011. The FDA indicated one or more additional trials comparing Lemtrada with another drug are needed for approval, Sanofi said. That would delay the product’s entry to a market dominated by Teva Pharmaceutical Industries Ltd. (TEVA:US)’s Copaxone, Biogen Idec Inc. (BIIB:US)’s Tecfidera, Avonex and Tysabri, Novartis AGâs (NOVN) Gilenya and Merck KGaA’s Rebif.
Read more »
Labels: Avonex, Copaxone, Lemtrada, Rebif, Tecfidera, Tysabri
BioTrends Research Group Rolls Out The TreatmentTrends: Multiple Sclerosis 2013 Report
BioTrends Research Group, a research and advisory firms for specialized biopharmaceutical issues, finds that physician-reported patient shares for Novartis's Gilenya and Biogen Idec's Tysabri are 8 percent and 10 percent among relapsing-remitting multiple sclerosis (RR-MS) patients treated with a disease-modifying therapy (DMT) across the EU5 (France, Germany, Italy, Spain and the United Kingdom); significantly higher than those reported by EU5 neurologists surveyed in 2012.
According to a release, surveyed neurologists also report that recent changes in treatment management include a shift toward earlier and more-aggressive treatment and increased use of the anti- JCV antibody assay, changes that are consistent with the increased patient shares reported for Gilenya and Tysabri. Survey data indicate that these agents occupy distinct niches, with Gilenya a preferred second-line therapy in JCV-positive patients and Tysabri a preferred second-line therapy in JCV-negative patients.
The TreatmentTrends: Multiple Sclerosis (EU) 2013 report finds that, despite fewer than 30 percent of surveyed neurologists reporting access to Genzyme's* Aubagio and Genzyme/Bayer HealthCare's Lemtrada--and given the limited time these agents had been available at the time the survey was fielded--these DMTs have nevertheless captured a 1 percent physician-reported weighted MS patient share. The data also reveal that surveyed neurologists anticipate substantial changes in DMT use in the coming months as access to Aubagio and Lemtrada expands and as new products, notably Biogen Idec's Tecfidera, become available. Neurologists indicate that Aubagio will most likely compete with first-line products (i.e., Biogen Idec's Avonex, Bayer HealthCare's Betaferon and Teva's Copaxone), while Tecfidera may replace these products as well as Merck Serono's Rebif and Gilenya. Lemtrada, conversely, will most likely compete with Tysabri or would not replace an existing DMT, suggesting anticipated use as a last-line therapy.
"The European MS market is entering a dynamic period with two recent DMT launches and as many as six new DMTs launching in the next five years," said Decision Resources Group Senior Business Insights Analyst Georgiana L. Kuhlmann, S.M. "Our data find that gains for new brands will likely come at the expense of the interferon-beta therapies and Copaxone."
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets.
Decision Resources Group is a cohesive portfolio of companies that offers information and insights on sectors of the healthcare industry.
Read more »
Labels: Aubagio, Avonex, Betaseron, Copaxone, Lemtrada, Rebif, Tecfidera, Tysabri
Daniel Kantor, MD, on Specialty Pharmacy in Multiple Sclerosis
In
the last two decades we’ve seen really an explosion of the treatments
we have for multiple sclerosis (MS),” said Daniel Kantor, MD, medical
director, Neurologique, immediate past president, Florida Society of
Neurology. Until recently, self-injectables and intravenous medications
were the only treatment options available for patients diagnosed with MS
making specialty pharmacy, “hugely important for the treatment of MS.”
Today, there are 10 disease-modifying agents approved by the US Food and
Drug Administration:
- See more at:
http://www.ajmc.com/conferences/ectrims2013/Daniel-Kantor-MD-on-Specialty-Pharmacy-in-Multiple-Sclerosis-#sthash.qllKQSe0.dpuf
- Aubagio (teriflunomide)
- Avonex (interferon beta-1a)
- Betaseron (interferon beta-1b)
- Copaxone (glatiramer acetate)
- Extavia (interferon beta-1b)
- Gilenya (fingolimod)
- Novantrone (mitoxantrone)
- Rebif (interferon beta-1a)
- Tecfidera (dimethyl fumarate)
- Tysabri (natalizumab)
Dr
Kantor notes that specialty pharmacies ensure facilities and patients
receive medications in a timely manner. Specialty pharmacies also play a
crucial role in both patient education and adherence.
“In
the last two decades we’ve seen really an explosion of the treatments
we have for multiple sclerosis (MS),” said Daniel Kantor, MD, medical
director, Neurologique, immediate past president, Florida Society of
Neurology. Until recently, self-injectables and intravenous medications
were the only treatment options available for patients diagnosed with MS
making specialty pharmacy, “hugely important for the treatment of MS.”
Today, there are 10 disease-modifying agents approved by the US Food and
Drug Administration:
- See more at:
http://www.ajmc.com/conferences/ectrims2013/Daniel-Kantor-MD-on-Specialty-Pharmacy-in-Multiple-Sclerosis-#sthash.qllKQSe0.dpuf
- Aubagio (teriflunomide)
- Avonex (interferon beta-1a)
- Betaseron (interferon beta-1b)
- Copaxone (glatiramer acetate)
- Extavia (interferon beta-1b)
- Gilenya (fingolimod)
- Novantrone (mitoxantrone)
- Rebif (interferon beta-1a)
- Tecfidera (dimethyl fumarate)
- Tysabri (natalizumab)
Dr
Kantor notes that specialty pharmacies ensure facilities and patients
receive medications in a timely manner. Specialty pharmacies also play a
crucial role in both patient education and adherence.
“In
the last two decades we’ve seen really an explosion of the treatments
we have for multiple sclerosis (MS),” said Daniel Kantor, MD, medical
director, Neurologique, immediate past president, Florida Society of
Neurology. Until recently, self-injectables and intravenous medications
were the only treatment options available for patients diagnosed with MS
making specialty pharmacy, “hugely important for the treatment of MS.”
Today, there are 10 disease-modifying agents approved by the US Food and
Drug Administration:
- See more at:
http://www.ajmc.com/conferences/ectrims2013/Daniel-Kantor-MD-on-Specialty-Pharmacy-in-Multiple-Sclerosis-#sthash.qllKQSe0.dpuf
- Aubagio (teriflunomide)
- Avonex (interferon beta-1a)
- Betaseron (interferon beta-1b)
- Copaxone (glatiramer acetate)
- Extavia (interferon beta-1b)
- Gilenya (fingolimod)
- Novantrone (mitoxantrone)
- Rebif (interferon beta-1a)
- Tecfidera (dimethyl fumarate)
- Tysabri (natalizumab)
Dr
Kantor notes that specialty pharmacies ensure facilities and patients
receive medications in a timely manner. Specialty pharmacies also play a
crucial role in both patient education and adherence.
See Video Here
Labels: Aubagio, Avonex, Betaseron, Copaxone, Extavia, Novantrone, Rebif, Tecfidera, Tysabri